FDA Expediting Review of Regeneron Drug to Treat Genetic Hearing Loss
Regeneron’s DB-OTO gene therapy for genetic hearing loss is one of nine drugs to receive expedited review under FDA's new CNPV program.
Regeneron’s DB-OTO gene therapy for genetic hearing loss is one of nine drugs to receive expedited review under FDA's new CNPV program.
Finnish researchers have been the first to determine the cause for the nonsyndromic early-onset hereditary canine hearing loss in Rottweilers, according to an announcement published on the University of Helsinki website.